Higher excess deaths during Omicron period has been found when compared to Delta period in Massachusetts as per a study at the Brigham and Women’s Hospital.
US FDA Declines to Authorize Fluvoxamine for Covid-19 Treatment
Fluvoxamine, an antidepressant drug, was not approved by the US Food and Drug Administration (FDA) for treating Covid-19.
Fluvoxamine, an antidepressant drug, was not approved by the US Food and Drug Administration (FDA) for treating Covid-19.
‘New study compares excess deaths during the pandemic period when the Delta variant dominated, during the transition from Delta to the Omicron variant and when Omicron dominated in Massachusetts.’
New study compares excess deaths during the pandemic period when the Delta variant dominated (June 28, 2021-December 5, 2021), during the transition from Delta to the Omicron variant (December 6-26, 2021) and when Omicron dominated (December 27, 2021-February 20, 2022) in Massachusetts. Investigators found that excess deaths were higher during the 8-week Omicron period compared to the 23-week Delta period (2,294 deaths versus 1,975).
“In terms of excess death, we found that Omicron was actually much worse for Massachusetts than Delta,” said Faust. “Others have reported that the Omicron variant may cause milder COVID-19. Assuming that’s the case, what we’re seeing here may reflect just how much more infectious Omicron has been. This could mean that highly contagious variants, even if they cause relatively milder illness, can still lead to substantial excess mortality, even in a highly vaccinated population.”
Source-Newswise
